Abstract 5271
Background
Clinical trials improve our knowledge of diseases and treatments while providing patients access to investigational agents. However, approximately 3% of newly diagnosed cancer patients are enrolled in clinical trials in the United States. Identifying an appropriate trial for a patient is time-consuming and cumbersome in the busy clinical practice. The Watson for Clinical Trial Matching (CTM) cognitive system uses AI to derive patient and cancer-related attributes from structured and unstructured text found in the electronic health record. These attributes are matched to complex eligibility criteria in clinical trial protocols.
Methods
In April 2019, a pilot study was launched to test the feasibility of implementing CTM in Gastrointestinal (GI) oncology at Mayo Clinic in Rochester, MN. Two clinical research coordinators (CRCs) screened patients for potential clinical trials prior to their clinic visits using both CTM and the traditional manual screening method. To avoid bias, each CRC screened a separate set of patients by both methods alternating which methodology was used first. The clinical trial match results were blinded to both CRCs. For each method, time to complete the screen and number of potential clinical trial matches were recorded.
Results
A total of 35 GI cancer patients with new diagnosis, recent resection or restaging scans were analyzed. Patients were evaluated against 50 GI-specific drug therapy and multi-disease phase I clinical trials. Clinical trial matching using CTM took an average of 10.1 minutes (Range: 4 to 20 min) per patient compared to an average of 30.5 minutes (Range: 5 to 75 min) per patient (p < 0.0001) using the manual method. CTM identified an average of 7.66 clinical trials (Range: 0-16) while the manual screening method identified an average of 1.97 clinical trials (Range: 0 to 6) per patient (p < 0.0001).
Conclusions
Implementation of Watson for CTM system with a CRC team may enable high volume patient screening for a large number of clinical trials in an efficient manner and promote awareness of clinical trial opportunities within the GI oncology practice. Further analysis to evaluate CTM accuracy and impact on enrollment is warranted and currently underway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Mayo Clinic.
Disclosure
T. Haddad: Advisory / Consultancy: TerSera Therapeautics; Research grant / Funding (self): Takeda. S. Coverdill: Full / Part-time employment: IBM Watson Health; Shareholder / Stockholder / Stock options: IBM. M. Rammage: Full / Part-time employment: IBM Watson Health; Licensing / Royalties: IBM. All other authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract